National Quality Measure Compliance for Palliative Bone Radiation Among Patients With Metastatic Non–Small Cell Lung Cancer
Search for other papers by Stephen R. Grant in
Current site
Google Scholar
PubMed
Search for other papers by Benjamin D. Smith in
Current site
Google Scholar
PubMed
Search for other papers by Lauren E. Colbert in
Current site
Google Scholar
PubMed
Search for other papers by Qunyh-Nhu Nguyen in
Current site
Google Scholar
PubMed
Search for other papers by James B. Yu in
Current site
Google Scholar
PubMed
Search for other papers by Steven H. Lin in
Current site
Google Scholar
PubMed
Search for other papers by Aileen B. Chen in
Current site
Google Scholar
PubMed
Background: There exists wide practice variability in palliative treatment schedules for bone metastases. In an effort to reduce variation and promote high-quality, cost-conscious care, the National Quality Forum (NQF) endorsed measure 1822 in 2012. This measure recommends the use of 30 Gy in 10 fractions, 24 Gy in 6 fractions, 20 Gy in 5 fractions, or 8 Gy in a single fraction for palliative radiation for bone metastases. We report on longitudinal compliance with this measure. Methods: Using the National Cancer Database, patients with metastatic thoracic non–small cell lung cancer diagnosed between 2004 and 2016 who received radiation therapy for bony sites of metastatic disease were identified. Treatment courses fitting 1 of the 4 recommended schedules under NQF 1822 were coded as compliant. Rates of compliance by patient, tumor, and treatment characteristics were analyzed. Results: A total of 42,685 patients met the criteria for inclusion. Among all patients, 60.2% of treatment courses were compliant according to NQF 1822. Compliance increased over time and was highest for treatments to the extremity (69.8%), lowest for treatments to the skull or head (48.8%), and higher for academic practice (67.1%) compared with community (56.0%) or integrated network facilities (61.2%). On multivariable analysis, predictors of NQF 1822 compliance included year of diagnosis after 2011, treatment to an extremity, or treatment at an academic facility. Of noncompliant treatment courses, extended fractionation (≥11 fractions) occurred in 62.6% and was more common before 2012, in community practice, and for treatments of the skull or head. Conclusions: Among patients treated for metastatic non–small cell lung cancer, compliance with NQF 1822 increased over time. Although extended fractionation constituted a majority of noncompliant treatment courses, a substantial proportion also involved shorter courses.
Submitted July 21, 2020; accepted for publication November 17, 2020. Published online May 26, 2021.
Author contributions: Study concept and design: Grant, Lin, Chen. Data acquisition, analysis, and interpretation: Grant, Chen. Manuscript - original draft: Grant. Manuscript - review and editing: All authors.
Disclosures: The authors have disclosed that they have not received any financial consideration from any person or organization to support the preparation, analysis, results, or discussion of this article.
© 2019-2024 National Comprehensive Cancer Network